mRNA 1083
Alternative Names: COVID+Flu vaccine - Moderna Therapeutics; mRNA-1083; mRNA-1083.1; mRNA-1083.2; mRNA-1083.3Latest Information Update: 12 May 2025
At a glance
- Originator Moderna Therapeutics
- Class COVID-19 vaccines; Influenza virus vaccines; RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration COVID 2019 infections; Influenza virus infections
Most Recent Events
- 12 May 2025 Suspended - Phase-II for COVID-2019 infections (Prevention, In adults) in USA (IM)
- 12 May 2025 Suspended - Phase-II for Influenza virus infections (Prevention, In adults) in USA (IM)
- 01 May 2025 Moderna recives the feedback from US FDA confirming the need for phase III trial efficacy data for regulatory approval